Structure Therapeutics Inc.
GPCR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001888886
No open-market purchases or sales by Structure Therapeutics Inc. insiders were filed in the last 90 days; 191 institutions reported holding it in 13F filings for Q2 2026, worth $3.62B in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Structure Therapeutics Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 151 | 173 | +22 |
| Shares | 56.4M | 54.8M | −1.57M (−2.8%) |
| Value | $990.0M | $1.14B | +$147.5M (+14.9%) |
New holders (38)
Institutions that held Structure Therapeutics Inc. at the end of Q2 2025 but not at the end of Q1 2025.
Sold out (16)
Institutions that held Structure Therapeutics Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Capital Research Global Investors | 2,164,145 | $37.5M |
| FIL Ltd | 1,150,440 | $19.9M |
| Camber Capital Management LP | 300,000 | $5.19M |
| Candriam Luxembourg S.C.A. | 214,063 | $3.71M |
| Balyasny Asset Management LLC | 202,483 | $3.50M |
| Jane Street Group, LLC | 120,703 | $2.09M |
| Zimmer Partners, LP | 100,776 | $1.74M |
| Wexford Capital LP | 30,102 | $521.1K |
| HRT Financial LP | 22,859 | $395.0K |
| Graham Capital Management, L.P. | 11,908 | $206.1K |
| Penserra Capital Management LLC | 3,411 | $59.0K |
| Boston Private Wealth LLC | 836 | $14.5K |
| CoreCap Advisors, LLC | 77 | $1.33K |
| Clearstead Advisors, LLC | 67 | $1.16K |
| Mather Group, LLC. | 35 | $606 |
| Larson Financial Group LLC | 9 | $156 |